# Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Article · Jennifer G. Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Rocco Averna, Erik S.G. Stroes, Gisle Langslet, Frederick Johan Raal, Mahfouz El Shahawy, Michael J. Koren, Norman E. Lepor, Christelle Lorenzato, Robert C. Pordy, Umesh Chaudhari, John J.P. Kastelein

- Archive id: doi:10.1056/nejmoa1501031
- Published: 2015-03-15
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa1501031
- PMID: 25773378
- Citations: 2,295
- Source URL: https://doi.org/10.1056/nejmoa1501031
- PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031?articleTools=true
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.